Aptamer-target interaction descriptor
Aptamer-target interaction information
Interaction ID: 389
Aptamer sequence: GGCGUGACCUGAUGAGUCACGCUAAGGAGGAUUUCCGAAAGCGGCUACGGUCCGCCAGUGUUACGAAACGUUCCC
Target unique ID: P28482
Aptamer ID Aptamer descriptor Target chemistry Target name Affinity Binding Conditions/Buffer PubMed ID
Apta_383 N Protein MK01_HUMAN 2 nM 10 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 0.05 μg/μl tRNA 12118241
Structure information of aptamer
Aptamer Sequence: GGCGUGACCUGAUGAGUCACGCUAAGGAGGAUUUCCGAAAGCGGCUACGGUCCGCCAGUGUUACGAAACGUUCCC
The optimal secondary structure in dot-bracket notation: ((((((((.......))))))))..((((..((((.....(((((........))).)).....))))..)))).
The centroid secondary structure in dot-bracket notation: ((((((((.......))))))))..((((..((((.............................))))..)))).
The MFE structure
The Centroid structure
The mountain plot representation
Aptamer information
Type Detail Type Detail
Aptamer ID Apta_383 Description N
Aptamer chemistry RNA Length 75 nt
GC content 57.3% Molecular weight 24,170.38 Da
Molarity of 1 μg/μl solution 41.37 μM Number of G-quadruplexes No QGRS found
G-Score N/A Function Targeted binding
Sequence GGCGUGACCUGAUGAGUCACGCUAAGGAGGAUUUCCGAAAGCGGCUACGGUCCGCCAGUGUUACGAAACGUUCCC
Applications Monitoring post-translational modification of proteins
Target information
Type Detail Type Detail
Uniprot ID P28482 Protein name Mitogen-activated protein kinase 1 (MAP kinase 1) (MAPK 1) (EC 2.7.11.24) (ERT1) (Extracellular signal-regulated kinase 2) (ERK-2) (MAP kinase isoform p42) (p42-MAPK) (Mitogen-activated protein kinase 2) (MAP kinase 2) (MAPK 2)
Gene name(s) MAPK1 ERK2 PRKM1 PRKM2 Organism Mitogen-activated protein kinase 1 (MAP kinase 1) (MAPK 1) (EC 2.7.11.24) (ERT1) (Extracellular signal-regulated kinase 2) (ERK-2) (MAP kinase isoform p42) (p42-MAPK) (Mitogen-activated protein kinase 2) (MAP kinase 2) (MAPK 2)
Status reviewed in uniprot database Length 360
Mass 41,390 Activity regulation Phosphorylated by MAP2K1/MEK1 and MAP2K2/MEK2 on Thr-185 and Tyr-187 in response to external stimuli like insulin or NGF
Involvement in disease Noonan syndrome 13 (NS13) Catalytic activity Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-[protein]
PDB ID(s)
1PME;1TVO;1WZY;2OJG;2OJI;2OJJ;2Y9Q;3D42;3D44;3I5Z;3I60;3SA0;3TEI;3W55;4FMQ;4FUX;4FUY;4FV0;4FV1;4FV2;4FV3;4FV4;4FV5;4FV6;4FV7;4FV8;4FV9;4G6N;4G6O;4H3P;4H3Q;4IZ5;4IZ7;4IZA;4N0S;4NIF;4O6E;4QP1;4QP2;4QP3;4QP4;4QP6;4QP7;4QP8;4QP9;4QPA;4QTA;4QTE;4XJ0;4ZXT;4ZZM;4ZZN;4ZZO;5AX3;5BUE;5BUI;5BUJ;5BVD;5BVE;5BVF;5K4I;5LCJ;5LCK;5NGU;5NHF;5NHH;5NHJ;5NHL;5NHO;5NHP;5NHV;5V60;5V61;5V62;5WP1;6D5Y;6DMG;6G54;6G8X;6G91;6G92;6G93;6G97;6G9A;6G9D;6G9H;6G9J;6G9K;6G9M;6G9N;6GDM;6GDQ;6GE0;6GJB;6GJD;6NBS;6OPG;6OPH;6OPI;6Q7K;6Q7S;6Q7T;6QA1;6QA3;6QA4;6QAG;6QAH;6QAL;6QAQ;6QAW;6RQ4;6SLG;7AUV;7E73;7E75;7NQQ;7NQW;7NR3;7NR5;7NR8;7NR9;7OPM;7W5O;
Function Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway.
Activity data

No relevant experimental diagram

Interaction ID 389
Target type Protein
Target unique ID P28482
Activity 2 nM
Binding Conditions/Buffer

10 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 0.05 μg/μl tRNA

Assay

N/A

PubMed ID 12118241
Similar aptamers
Aptamer ID Aptamer chemistry Sequence Similarity
Apta_382 RNA GGCGUGACCUGAUGAGUCACGCAGACGCUAGCGAAUUGGUUCCUCGAAAGGGGAAAGCGUUAUUAAGAAACCAAAAUGUGUUACGAAACGUUCCC 69.47%
Apta_522 RNA GGGCGACCCUGAUGAGCACACGAGGGGGAAACCCCGGACAAUCAGACACGGUGUUCGAAACGGUGAAAGCCGUAGGUUGCCCUUU 57.65%
Apta_612 RNA GGGCGACCCUGAUGAGCCUUAGGAUAUGCUUCGGCAGAAGGACGUCGAAACGGUGAAAGCCGUAGGUUGCCC 56.00%
Apta_1222 RNA GGAGGCGCCAACUGAAUGAAACCGUGCUAAGGAGUUGGACUCCGCUGCUUCGGCAGAGCGAUAUAGUGCCAGCUGAUACAUCCGUAACUAGUCGCGUCAC 54.00%
Apta_1223 RNA GGAGGCGCCAACUGAAUGAAAGGUUACGCUUCAACGCCGUGCAGCUGCUUCGGCAGGCUUGUGAGUACAUGGCCCAUUGAUCCGUAACUAGUCGCGUCAC 54.00%
Apta_1248 RNA GGGUGACUUUUCCCUCAGGCUCCUGUGAAGCAACCGAAUGGACUGAAAUGAAACCGCCC 53.33%
Apta_1224 RNA GGAGGCGCCAACUGAAUGAAUGUUCUGGAUCUGCUAGAGACUAUCUGCUUCGGCAGCACUCUCCGUUAACAACACGUACAUCCGUAACUAGUCGCGUCAC 53.00%
Apta_1225 RNA GGAGGCGCCAACUGAAUGAAAGAGGUAACGAAAGAUGAUUGUGCCUGCUUCGGCAGUACAACUUCUCGGAUAAAUGAUUAUCCGUAACUAGUCGCGUCAC 53.00%
Apta_6 RNA GGAAAGACGCUAGCGAAUUGGUUCCUCGAAAGGGGAAAGCGUUAUUAAGAAACCAAAAUUUCC 52.00%
Apta_155 RNA GACCCAGGGCCGGGACGCAAAGCAGCCAAAACAGACGGCCCCAGUCAGGGAGUU 52.00%
Apta_305 RNA GGGAGGACGAUGCGGAUCGCCCUGAACCGGCCCAGCAGACUGCUGACGGCACGAUCCGCAUCGUCCUCCC 52.00%
Apta_314 RNA GGUUACCAGCCUUCACUGCUCCCGGACGCGUCUGUAUCCGCUACCCGCCGCACCACGGUCGGUCACAC 52.00%
Apta_424 RNA UGCUAGUAUAUCGCACGGAUUUAAUCGCCGUAGAAAAGCAUGUCAAAGCCG 52.00%
Apta_425 RNA UGCCGCCAUAUCACACGGAUUUAAUCGCCGUAGAAAAGCAUGUCAAAGCCG 52.00%
Apta_453 RNA GGGCUAGCUGAUCGUACCAGUAGCGUGGCCUGGGGGGCCUAGUCGUGCGAUACUAACAGCUAACACCC 52.00%
Apta_1226 RNA GGAGGCGCCAACUGAAUGAAGGUGUAUUUCAGUUAAAGAACUUGCUGCUUCGGCAGCGUUCUGAGUUACUAGUCCAAUAAUCCGUAACUAGUCGCGUCAC 52.00%
Apta_723 RNA GGGAGCUCAGAAUAAACGCUCAAAUCCGUGGACAGGGCGUAAGCGCCUUCGACAUGAGACACGGAUCCUGCGACGAAUUCAGC 51.81%
Apta_376 RNA GGGAGCUCAGCCUUCACUGCACUCCGGCUGGUGGACGCGGUACGAGCAAUUUGUACCGGAUGGAUGUUCGGGCAGCGGUGUGGCAGGGAUGAGCGGCACCACGGUCGGAUCCAC 51.75%
Apta_854 RNA GGGAGCUCAGAAUAAACGCUCAAGGGUAGGGAUCGUUACCCCGACAUUUUAAUGGGCCGAUGUUUCGACAUGAGGCCCGGAUCCGGC 51.72%
Apta_598 RNA GGGAAUUCCGCGUGUGCGCCGCGGAAGACGUUGGAAGGAUAGAUACCUACAACGGGGAAUAUAGAGGCCAGCACAUAGUGAGGCCCUCCUCCC 51.61%